HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
Read original at benzingaStocks · News reference
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 12:02 PM
- Checked
- Aug 20, 2026, 12:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Read original at benzingaRein Therapeutics Announces Nature Communications Publication Of First-In-Human LTI-03 Data In 24 IPF Patients, Says Drug Reduced Multiple Fibrosis And Inflammation Markers
Read original at benzinga